Form 4: Disc Medicine COO Sells Shares After Option Exercise

Disc Medicine's Chief Operating Officer, Jonathan Yen-Wen Yu, exercised stock options and subsequently sold 30,000 shares of common stock for a significant profit.

Summary

• Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc. (IRON), engaged in transactions involving the company's common stock.
• On November 11, 2025, Mr. Yu exercised stock options to acquire 30,000 shares of common stock at an exercise price of $2.65 per share.
• Immediately following the option exercise on November 11, 2025, Mr. Yu sold a total of 30,000 shares of common stock in multiple transactions.
• The sales were executed at weighted average prices ranging from $83.1453 to $85.9129 per share.
• Specifically, 8,015 shares were sold at a weighted average price of $83.1453, 4,585 shares at $83.9877, 9,360 shares at $85.3301, and 8,040 shares at $85.9129.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on July 22, 2025.
• Following these transactions, Mr. Yu directly beneficially owns 40,555 shares of common stock and 7,941 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions represent a routine insider activity (option exercise and sale) executed under a pre-arranged 10b5-1 trading plan. While the officer realized a significant personal profit, the reduction in direct share ownership is balanced by the pre-planned nature of the sale, which typically indicates personal financial management rather than a specific positive or negative signal about the company's immediate prospects.

Positives

• The Chief Operating Officer realized a significant profit by exercising stock options at a low price ($2.65) and selling shares at substantially higher market prices (ranging from $82.63 to $86.28).

Negatives

• The Chief Operating Officer reduced his direct beneficial ownership of common stock by 30,000 shares, which could be perceived as a slight reduction in insider alignment, although it was part of a pre-arranged plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report (Form 4) is a routine disclosure required by the SEC and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock activity.

Stakeholder Impact

• Shareholders: The transaction results in a slight decrease in direct insider ownership, which is a routine event for pre-planned sales and generally has minimal direct impact on other shareholders. The significant profit realized by the COO could be seen as a positive for executive compensation alignment.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged Rule 10b5-1 trading plan. This type of transaction typically reflects personal financial planning by the officer rather than a direct signal about the company's operational performance or future prospects. While the officer reduced their direct shareholding, the transaction was planned months in advance and does not inherently suggest a change in the company's fundamental value or outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to warrant a change in investment thesis.

Keywords

Disc Medicine, IRON, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Jonathan Yu, COO, Rule 10b5-1